Abstract

Experience of COVID 19 disease on 159 Ecuadorian chronic dialysis patients

Highlights

  • 1.4.3.4: We recommend that clinical laboratories should (1B): K measure serum creatinine using a specific assay with calibration traceable to the international standard reference materials and minimal bias compared to isotope-dilution mass spectrometry (IDMS) reference methodology

  • 3.1.11: We suggest that an angiotensin-receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACE-I) be used in children with CHRONIC KIDNEY DISEASE (CKD) in whom treatment with blood pressure (BP)-lowering drugs is indicated, irrespective of the level of proteinuria. (2D)

  • We suggest that people with levels of intact parathyroid hormone (PTH) above the upper normal limit of the assay are first evaluated for hyperphosphatemia, hypocalcemia, and vitamin D deficiency. (2C)

Read more

Summary

136 References

This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE) www.publicationethics.org. 2012 CKD-EPI creatinine–cystatin C equation: 135  min(SCr/k, 1)a  max(SCr/k, 1)À0.601  min(SCysC/0.8, 1)À0.375  max(SCysC/ 0.8, 1)À0.711  0.995Age [  0.969 if female] [  1.08 if black], where SCr is serum creatinine (in mg/dl), SCysC is serum cystatin C (in mg/l), k is 0.7 for females and 0.9 for males, a is À0.248 for females and À0.207 for males, min(SCr/k, 1) indicates the minimum of SCr/k or 1, and max(SCr/k, 1) indicates the maximum of SCr/k or 1; min(SCysC/0.8, 1) indicates the minimum of SCysC/0.8 or 1 and max(SCysC/ 0.8, 1) indicates the maximum of SCysC/0.8 or 1. Prognosis of CKD by GFR and Albuminuria Categories: KDIGO 2012. GFR categories (ml/min/ 1.73 m2) Description and range

Kidney failure
SECTION II: DISCLOSURE Kidney Disease
1.1: DEFINITION OF CKD
1.2: STAGING OF CKD
1.3: PREDICTING PROGNOSIS OF CKD
1.4: EVALUATION OF CKD
2.1: DEFINITION AND IDENTIFICATION OF CKD PROGRESSION
2.2: PREDICTORS OF PROGRESSION
3.1: PREVENTION OF CKD PROGRESSION
3.2: COMPLICATIONS ASSOCIATED WITH LOSS OF KIDNEY FUNCTION
3.3: CKD METABOLIC BONE DISEASE INCLUDING LABORATORY ABNORMALITIES
4.2: CAVEATS WHEN INTERPRETING TESTS FOR CVD IN PEOPLE WITH CKD
4.3: CKD AND PERIPHERAL ARTERIAL DISEASE
4.4: MEDICATION MANAGEMENT AND PATIENT SAFETY IN CKD
4.5: IMAGING STUDIES
5.1: REFERRAL TO SPECIALIST SERVICES
5.2: CARE OF THE PATIENT WITH PROGRESSIVE CKD
5.3: TIMING THE INITIATION OF RRT
5.4: STRUCTURE AND PROCESS OF COMPREHENSIVE CONSERVATIVE MANAGEMENT
STAGING OF CKD
1.4.1: Evaluation of chronicity
1.4.2: Evaluation of cause
Results
Methods
Evaluation of albuminuria
PREVENTION OF CKD PROGRESSION
COMPLICATIONS ASSOCIATED WITH LOSS OF KIDNEY FUNCTION
CKD METABOLIC BONE DISEASE INCLUDING LABORATORY ABNORMALITIES
ACIDOSIS
CKD and CVD
CAVEATS WHEN INTERPRETING TESTS FOR CVD IN PEOPLE WITH CKD
CKD AND PERIPHERAL ARTERIAL DISEASE
MEDICATION MANAGEMENT AND PATIENT SAFETY IN CKD
LIMITATIONS
Analgesics NSAIDS
Antimicrobials Penicillin
Hypoglycemics Sulfonylureas
Lipid-lowering Statins
Anticoagulants Low-molecular-weight heparins
Miscellaneous Lithium
Methods for guideline development
Study design
15. Potential benefits and harm
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call